Fungal diseases

Cidara Therapeutics to Present New Analyses for Rezafungin at the 31st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

Retrieved on: 
Wednesday, June 30, 2021
Animal diseases, Fungal diseases, Infectious diseases, Sepsis, Antifungals, Echinocandin, Invasive candidiasis, Candidiasis, Fungemia, Mycosis, Draft:David Wemyss Denning, Candida albicans

Rezafungin is a novel once-weekly echinocandin currently being studied in Phase 3 trials for the treatment and prevention of serious fungal infections incriticallyilland cancer patients.

Key Points: 
  • Rezafungin is a novel once-weekly echinocandin currently being studied in Phase 3 trials for the treatment and prevention of serious fungal infections incriticallyilland cancer patients.
  • Rezafungin is a novel once weekly echinocandin being developed for both the treatment and prevention of serious fungal infections, such as candidemia and invasive candidiasis.
  • The structure and properties of rezafungin are specifically designed to improve upon a clinically validated mechanism intended to enhance its efficacy and safety potential for patients.
  • Cidara is developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections.

TLC Announces Approval of New Drug Application of Liposomal Amphotericin B in India

Retrieved on: 
Tuesday, May 25, 2021
Infectious diseases, Medical specialties, Fungal diseases, Antifungals, Polyenes, Amphotericin B, Mucormycosis, Mycosis

AmphoTLC is a liposomal amphotericin B injection indicated for severe systemic fungal infections such as mucormycosis.

Key Points: 
  • AmphoTLC is a liposomal amphotericin B injection indicated for severe systemic fungal infections such as mucormycosis.
  • The increasing number of CAM cases has resulted in unprecedently high demand for liposomal amphotericin B, the key drug to treat mucormycosis, causing an acute shortage of the drug.
  • Exploitation by sellers on the black market, who are marking up the price of liposomal amphotericin B by three times, is further exacerbating the situation.
  • The registration allows for immediate importation of AmphoTLC as per approved usage and indication of liposomal amphotericin B in India, which includes mucormycosis, to help alleviate the urgent need for the drug.

Global Systemic Aspergillosis and Systemic Candidiasis Market Forecast to 2027 - COVID-19 Impact and Analysis

Retrieved on: 
Thursday, March 18, 2021
Fungal diseases, Drugs, Chemical compounds, Antifungals, Polyenes, Sepsis, Candidiasis, Amphotericin B, Aspergillosis, Invasive candidiasis, Voriconazole, Systemic

DUBLIN, March 18, 2021 /PRNewswire/ -- The "Systemic Aspergillosis and Systemic Candidiasis Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Type, and Geography" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, March 18, 2021 /PRNewswire/ -- The "Systemic Aspergillosis and Systemic Candidiasis Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Type, and Geography" report has been added to ResearchAndMarkets.com's offering.
  • According to this report the global systemic aspergillosis and systemic candidiasis market is expected to reach US$ 8,247.5 million by 2027 from US$ 6,056.3 million in 2019; it is estimated to grow at a CAGR of 4.0% from 2020 to 2027.
  • The report provides trends prevailing in the global systemic aspergillosis and systemic candidiasis market, and the drivers and hindrances pertaining to the market growth.
  • Based on type, the systemic aspergillosis and systemic candidiasis market is segmented into voriconazole, liposomal amphotericin b, systemic oral azoles, topical antifungal agents, and others.

Insights on the Systemic Aspergillosis and Systemic Candidiasis Global Market to 2027 - by Type and Geography - ResearchAndMarkets.com

Retrieved on: 
Monday, March 15, 2021
Health, Other Health, Branches of biology, Fungal diseases, Infectious diseases, Antifungals, Polyenes, Sepsis, Mycosis, Candidiasis, Amphotericin B, Aspergillosis, Invasive candidiasis, Voriconazole

The "Systemic Aspergillosis and Systemic Candidiasis Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Type, and Geography" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Systemic Aspergillosis and Systemic Candidiasis Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Type, and Geography" report has been added to ResearchAndMarkets.com's offering.
  • The report provides trends prevailing in the global systemic aspergillosis and systemic candidiasis market, and the drivers and hindrances pertaining to the market growth.
  • Based on type, the systemic aspergillosis and systemic candidiasis market is segmented into voriconazole, liposomal amphotericin b, systemic oral azoles, topical antifungal agents, and others.
  • Rise in prevalence of fungal diseases and increase in incidence of hospital-acquired fungal infection are the key factors driving the systemic aspergillosis and systemic candidiasis market.

Orphan Drug Designation Granted to Rezafungin in EU for the Treatment of Invasive Candidiasis

Retrieved on: 
Tuesday, January 26, 2021
Infectious diseases, Biotechnology, Pharmaceutical, Health, Fungal diseases, Antifungals, Branches of biology, Echinocandins, Infectious diseases, Sepsis, Invasive candidiasis, Caspofungin, Candidiasis, Fungemia, Esophageal candidiasis, Rezafungin, Mundipharma, Cidara Therapeutics

We are proud that patients affected with invasive candidiasis may have an additional treatment option to treat this potentially life-threatening condition.

Key Points: 
  • We are proud that patients affected with invasive candidiasis may have an additional treatment option to treat this potentially life-threatening condition.
  • We look forward to continuing to work closely with our colleagues at Mundipharma to advance rezafungin through late-stage clinical development.
  • Activity of a long-acting echinocandin, rezafungin, and comparator antifungal agents tested against contemporary invasive fungal isolates (SENTRY Program, 2016 to 2018).
  • Rezafungin versus Caspofungin in a Phase 2, Randomized, Double-Blind Study for the Treatment of Candidemia and Invasive Candidiasis- The STRIVE Trial.

Cidara Therapeutics to Present New Clinical Data for Rezafungin at ESICM LIVES 2020

Retrieved on: 
Monday, November 30, 2020
Fungal diseases, Infectious diseases, Medical specialties, Sepsis, Antifungals, Echinocandins, Invasive candidiasis, Candidiasis, Fungemia, Mycosis

Cidara will highlight analyses from the completed Phase 2 STRIVE trial of rezafungin for treatment of candidemia and/or invasive candidiasis.

Key Points: 
  • Cidara will highlight analyses from the completed Phase 2 STRIVE trial of rezafungin for treatment of candidemia and/or invasive candidiasis.
  • Rezafungin is a novel once-weekly echinocandin currently in pivotal Phase 3 trials for the treatment and prevention of serious fungal infections.
  • Additional details can be found in the Abstract Book from ESICM LIVES 2020 .
  • Cidara is developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections.

Cidara Therapeutics to Present at the 2020 American College of Clinical Pharmacy (ACCP) Annual Meeting

Retrieved on: 
Tuesday, October 13, 2020
Fungal diseases, Infectious diseases, Medical specialties, Sepsis, Antifungals, Echinocandins, Candidiasis, RTT, Invasive candidiasis, Mycosis, Fungemia

SAN DIEGO, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that it will present two posters at the 2020 American College of Clinical Pharmacy (ACCP) Annual Meeting, which takes place virtually from October 19-30, 2020.

Key Points: 
  • SAN DIEGO, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that it will present two posters at the 2020 American College of Clinical Pharmacy (ACCP) Annual Meeting, which takes place virtually from October 19-30, 2020.
  • Data being presented will highlight rezafungin, the Companys novel once-weekly echinocandin currently being evaluated in pivotal Phase 3 trials for the treatment and prevention of serious fungal infections.
  • Rezafungin is a novel once-weekly echinocandin being developed for both the treatment and prevention of serious fungal infections, such as candidemia and invasive candidiasis.
  • Cidara is developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections.

U.S. FDA Approves Supplemental New Drug Application (sNDA) for Expanded Indication of MYCAMINE® (micafungin for injection) for the Treatment of Invasive Candidiasis in Pediatric Patients Less Than 4 Months of Age

Retrieved on: 
Wednesday, January 8, 2020
Animal diseases, Health, Fungal diseases, RTT, Antifungals, Sepsis, Echinocandins, Candidiasis, Invasive candidiasis, Clinical trial, Micafungin

With the approval, MYCAMINE is the first antifungal drug approved in the United States specifically for the treatment of invasive candidiasis for this patient population.

Key Points: 
  • With the approval, MYCAMINE is the first antifungal drug approved in the United States specifically for the treatment of invasive candidiasis for this patient population.
  • "We're pleased with this decision and the potential benefits MYCAMINEmay offer to young infants and their families impacted by invasive candidiasis."
  • The safety of MYCAMINE was assessed in 168 pediatric patients younger than 4 months of age who received varying doses of MYCAMINE in nine clinical trials.
  • The approved dose for MYCAMINE in neonates and young infants less than four months is 4 mg/kg once daily.

Cidara Therapeutics to Present at Two Upcoming Medical Conferences

Retrieved on: 
Tuesday, December 3, 2019
Infectious diseases, Medicine, Fungal diseases, Sepsis, Antifungals, Echinocandins, RTT, Fungemia, Invasive candidiasis, Mycosis, Candidiasis, Infection

The presentation at the ASH Annual Meeting will highlight new preclinical data supporting Cidaras rezafungin program for the prevention of invasive fungal infections.

Key Points: 
  • The presentation at the ASH Annual Meeting will highlight new preclinical data supporting Cidaras rezafungin program for the prevention of invasive fungal infections.
  • The presentation at the Interdisciplinary Meeting on Anti-Infective Chemotherapy will provide an overview of Cidaras rezafungin clinical development program for the treatment and prevention of invasive fungal infections.
  • Cidara is currently advancing its novel echinocandin antifungal, rezafungin acetate, in a Phase 3 clinical trial for the first-line treatment of candidemia and/or invasive candidiasis (ReSTORE).
  • The Cloudbreak platform is designed to discover compounds that both directly kill pathogens and direct a patients immune system to attack and eliminate pathogens.

Cidara Therapeutics to Present New Clinical and Preclinical Data at Two Upcoming Medical Conferences

Retrieved on: 
Thursday, October 3, 2019
Animal diseases, Fungal diseases, Medicine, Sepsis, Antifungals, Echinocandins, Invasive candidiasis, Fungemia, Candidiasis, Pre-clinical development

The presentations at TIMM will highlight new clinical and preclinical data for rezafungin, including a late-breaking poster with top-line clinical data from a combined analysis of Parts A and B of the successfully completed STRIVE Phase 2 trial, which are being presented for the first time.

Key Points: 
  • The presentations at TIMM will highlight new clinical and preclinical data for rezafungin, including a late-breaking poster with top-line clinical data from a combined analysis of Parts A and B of the successfully completed STRIVE Phase 2 trial, which are being presented for the first time.
  • We are pleased to present these new updates from our advancing rezafungin and Cloudbreak programs to the IDSA and TIMM scientific communities, said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara.
  • A copy of the presentation materials can be accessed on the Publications section of the Cidara website once the presentations conclude.
  • Cidara is currently advancing its novel echinocandin antifungal, rezafungin acetate, in a Phase 3 clinical trial for the first-line treatment of candidemia and/or invasive candidiasis (ReSTORE).